Jury Awards $8 Billion in Risperdal Case Against Johnson & Johnson
Johnson & Johnson must pay $8 billion in punitive damages to a man who previously won $680,000 over his claims that it failed to warn that young men using its antipsychotic drug Risperdal could grow breasts, a Philadelphia jury said on Tuesday.
The Philadelphia Court of Common Pleas jury’s verdict in favor of Nicholas Murray came in the first case in which a Pennsylvania jury had been able to consider awarding punitive damages in one of thousands of Risperdal cases pending in the state.
The Philadelphia jury deliberating in the first punitive damages trial over Johnson & Johnson’s conduct in marketing the antispychotic drug Risperdal has slammed the company with an $8 billion verdict.
According to Thomas R. Kline of Kline & Specter, who tried the case along with Houston attorney Jason Itkin of Arnold & Itkin, the jury ruled 10-2 in awarding the multibillion-dollar verdict against the company, which he said is worth $60.7 billion.
Read the full article here.